Table 2.

TKB245 exerts potent activity against various SARS-CoV-2 variants

	Against SARS-CoV-2 variants EC50 (µM)
							KTKYX00012/ο	TKYVS2037/ο	TKYTS14631/ο	UT-NCD1757-1N/ο
Compound	WK521	QHN001/α	TY8-612/β	Y7-501/γ	K1734/δ	5356/k	BA.1	BA.2	BA.5	BA.2.75
TKB245	0.03 ± 0.02	0.042 ± 0.042	0.028 ± 0.009	0.056 ± 0.045	0.030 ± 0.003	0.020 ± 0.002	0.014 ± 0.001	0.045 ± 0.014	0.019 ± 0.005	0.049 ± 0.005
TKB248	0.22 ± 0.08	0.300 ± 0.001	0.287 ± 0.005	0.228 ± 0.061	0.273 ± 0.036	0.180 ± 0.035	0.282 ± 0.043	0.210 ± 0.087	0.070 ± 0.008	0.430 ± 0.091
Nirmatrelvir	0.94 ± 0.21	1.980 ± 0.559	1.498 ± 0.240	2.494 ± 0.292	1.499 ± 0.078	1.658 ± 0.606	1.047 ± 0.061	1.240 ± 0.125	1.080 ± 0.150	0.967 ± 0.135

Anti-SARS-CoV2 activity by compounds was evaluated with RT-qPCR of viral RNA from culture medium of SARS-CoV2-exposed VeroE6 cells. Each EC₅₀ value was calculated as previously published¹⁵. Data from three-four independent assays are shown as arithmetic means ± 1 S.D. Source data are provided as a Source Data file.